Breaking News Instant updates and real-time market news.

AQST

Aquestive Therapeutics

$7.74

-0.28 (-3.49%)

, BMRN

BioMarin

$78.87

-1.03 (-1.29%)

04:55
12/10/19
12/10
04:55
12/10/19
04:55

American Epilepsy Society to hold annual meeting

AES Annual Meeting 2019 will be held in Baltimore on December 6 -10.

AQST

Aquestive Therapeutics

$7.74

-0.28 (-3.49%)

BMRN

BioMarin

$78.87

-1.03 (-1.29%)

ESALY

Eisai

$0.00

(0.00%)

IART

Integra LifeSciences

$60.90

-1.34 (-2.15%)

NVTA

Invitae

$17.10

-0.59 (-3.34%)

LIVN

LivaNova

$80.46

-2.93 (-3.51%)

MNK

Mallinckrodt

$3.28

-0.12 (-3.53%)

MRNS

Marinus Pharmaceuticals

$1.27

-0.05 (-3.79%)

MDT

Medtronic

$111.12

-2.02 (-1.79%)

NTUS

Natus Medical

$31.37

-0.19 (-0.60%)

NVS

Novartis

$92.55

0.47 (0.51%)

PTCT

PTC Therapeutics

$48.22

-0.95 (-1.93%)

SUPN

Supernus

$22.69

-0.145 (-0.63%)

WTKWY

Wolters Kluwer

$0.00

(0.00%)

XENE

Xenon Pharmaceuticals

$13.86

-0.06 (-0.43%)

ZBH

Zimmer Biomet

$146.71

-1.84 (-1.24%)

ZGNX

Zogenix

$46.82

-0.02 (-0.04%)

  • 10

    Dec

  • 10

    Dec

  • 11

    Dec

  • 18

    Feb

  • 25

    Mar

  • 24

    May

AQST Aquestive Therapeutics
$7.74

-0.28 (-3.49%)

06/10/19
HCWC
06/10/19
NO CHANGE
Target $10
HCWC
Buy
Aquestive Therapeutics recent selloff unwarranted, says H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju believes the recent downward pressure on the stock has been unwarranted, particularly given the "faster-than-previously projected" progress of the Libervant PK study. The analyst reiterates a Buy rating on the shares with a $10 price target.
12/02/19
HCWC
12/02/19
NO CHANGE
Target $14
HCWC
Buy
Aquestive Therapeutics price target raised to $14 from $12 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Aquestive Therapeutics to $14 from $12 and reiterates a Buy rating on the shares. Earlier this month, Aquestive's licensee Sunovion announced the resubmission of its New Drug Application to the FDA for apomorphine sublingual film to treat motor fluctuations experienced by people living with Parkinson's disease in response to the Complete Response Letter received in late January 2019, Selvaraju tells investors in a research note. The resubmitted application included information about intended packaging as well as additional analyses of clinical data, which is an indication of Sunovion's continued commitment to the product and ought to pave the way for potential approval of the drug next year, says the analyst.
12/02/19
JMPS
12/02/19
NO CHANGE
Target $23
JMPS
Outperform
Aquestive Therapeutics NDA filing a positive sign, says JMP Securities
JMP Securities analyst Jason Butler reiterates an Outperform rating on Aquestive Therapeutics with a $23 price target after the company announced this morning that the final component of the rolling New Drug Application filing for Libervant has been completed. This is a positive sign of management's execution, says Butler, who looks forward to a likely 2020 launch of Libervant.
07/16/19
HCWC
07/16/19
NO CHANGE
Target $12
HCWC
Buy
Aquestive Therapeutics price target raised to $12 from $10 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Aquestive Therapeutics to $12 from $10 saying the company's financial burden is reduced following the completion of its $70M private placement. The refinancing "substantially reduces" Aquestive's quarterly interest payment burden and provides further financial flexibility during the period that may elapse before the company can achieve sustainable profitability, Selvaraju tells investors in a research note. He keeps a Buy rating on the shares.
BMRN BioMarin
$78.87

-1.03 (-1.29%)

11/27/19
LEHM
11/27/19
UPGRADE
Target $98
LEHM
Overweight
BioMarin upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Gena Wang upgraded BioMarin to Overweight from Equal Weight with a $98 price target.
12/03/19
SBSH
12/03/19
UPGRADE
Target $60
SBSH
Neutral
Audentes Therapeutics upgraded to Neutral from Sell at Citi
Citi analyst Mohit Bansal upgraded Audentes Therapeutics (BOLD) to Neutral from Sell with a price target of $60, up from $30, after the company agreed to be acquired by Astellas for $60 per share. The analyst says he "clearly underestimated big pharma's appetite for gene therapy." He thinks the premium paid by Astellas is based on value of technology and Audentes's preclinical pipeline. Gene therapy should continue to be a target, and BioMarin (BMRN) "could fit the bill," Bansal tells investors in a research note. The analyst expects gene therapy stocks to trade up on the Audentes deal.
11/27/19
11/27/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Under Armour (UA, UAA) upgraded to Strong Buy from Outperform at Raymond James with analyst Matthew McClintock saying he has become more comfortable with the company's risk/return profile, particularly regarding execution risk and valuation. 2. Dick's Sporting (DKS) upgraded to Outperform from In Line at Evercore ISI and to Overweight from Equal Weight at Barclays. 3. Masonite (DOOR) upgraded to Buy from Neutral at Northcoast. 4. BioMarin (BMRN) upgraded to Overweight from Equal Weight at Barclays with analyst Gena Wang saying she sees a favorable risk/reward into the Phase 3 data readout for vosoritide, which she expects will be positive. 5. Envestnet (ENV) upgraded to Buy from Hold at Sandler O'Neill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/27/19
LEHM
11/27/19
UPGRADE
Target $98
LEHM
Overweight
Barclays upgrades BioMarin to Overweight ahead of achondroplasia data
Barclays analyst Gena Wang upgraded BioMarin Pharmaceutical to Overweight from Equal Weight with a price target of $98, up from $86. The analyst sees a favorable risk/reward into the Phase 3 data readout for vosoritide, which she expects will be positive. Vosoritide's Phase 3 trial for treating achondroplasia is "well powered to allow for statistical significance," Wang tells investors in a research note. Further, the analyst believes BioMarin shares reflect little value for its hemophilia A gene therapy, ValRox.
ESALY Eisai
$0.00

(0.00%)

09/24/19
JEFF
09/24/19
INITIATION
JEFF
Buy
Eisai initiated with a Buy at Jefferies
Jefferies analyst Stephen Barker started Eisai with a Buy rating and 6,400 yen price target.
09/17/19
DAIW
09/17/19
DOWNGRADE
DAIW
Sell
Eisai downgraded to Sell from Neutral at Daiwa
Daiwa analyst Kazuaki Hashiguchi downgraded Eisai to Sell from Neutral with a price target of 3,400 yen, down from 6,600 yen.
08/05/19
SBSH
08/05/19
UPGRADE
SBSH
Neutral
Eisai upgraded to Neutral from Sell at Citi
Citi analyst Hidemaru Yamaguchi upgraded Eisai to Neutral from Sell.
10/24/19
NOMU
10/24/19
UPGRADE
NOMU
Buy
Eisai upgraded to Buy from Neutral at Nomura Instinet
Nomura Instinet analyst Motoya Kohtani upgraded Eisai (ESALY) to Buy from Neutral with a price target of 15,000 yen, up from 5,500 yen. The company's development partner Biogen (BIIB) announced that it plans to pursue regulatory approval for Alzheimer's disease treatment aducanumab in the U.S. following consultation with the FDA, Kohtani tells investors in a research note. The analyst thinks aducanumab is now more likely to become the world's first Alzheimer's disease modifying agent.
IART Integra LifeSciences
$60.90

-1.34 (-2.15%)

07/25/19
JMPS
07/25/19
NO CHANGE
Target $75
JMPS
Market Perform
Integra LifeSciences price target raised to $75 from $62 at JMP Securities
JMP Securities analyst David Turkaly raised his price target on Integra LifeSciences to $75 after its Q2 earnings beat and raised FY19 guidance, saying the results position the company "ahead of schedule" in achieving its operational and financial targets. The analyst adds that Integra's completed integration of Codman by Q3-end positions the company for organic growth of at least 5% in the second half of 2019.
07/24/19
PIPR
07/24/19
NO CHANGE
PIPR
Integra LifeSciences Q2 results better than expected, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien reiterated an Overweight rating and $69 price target on Integra LifeSciences after the company reported Q2 earnings results that were "ahead of expectations," with guidance the analyst believes is "likely conservative." O'Brien was also positive that the company's integration efforts look to be moving in the right direction, that orthopedics growth is improving, and that management remains committed to 100bps of GM expansion. He said Integra "now has a more favorable setup for the year (still at an attractive valuation)."
07/25/19
WELS
07/25/19
NO CHANGE
Target $68
WELS
Market Perform
Integra LifeSciences price target raised to $68 from $55 at Wells Fargo
Wells Fargo analyst Larry Biegelsen raised his price target for Integra LifeSciences to $68 from $55 as Q2 came in ahead of expectations, and the company raised its 2019 EPS outlook. The analyst reiterates a Market Perform rating on the shares.
07/25/19
OPCO
07/25/19
NO CHANGE
Target $70
OPCO
Outperform
Integra LifeSciences price target raised to $70 from $65 at Oppenheimer
Oppenheimer analyst Steven Lichtman raised his price target for Integra LifeSciences to $70 from $65 following quarterly results. The analyst reiterates an Outperform rating on the shares.
NVTA Invitae
$17.10

-0.59 (-3.34%)

07/12/19
BNCH
07/12/19
NO CHANGE
Target $26
BNCH
Buy
Invitae price target raised to $26 after Jungla deal announcement at Benchmark
Benchmark analyst Bruce Jackson raised his price target on Invitae shares to $26 from $22 following the company's announcement of a deal to acquire privately-held Jungla for $50M plus potential milestone payments. The analyst, who said the deal adds to Invitae's hereditary cancer testing capabilities, keeps a Buy rating on the stock.
04/08/19
OPCO
04/08/19
NO CHANGE
Target $30
OPCO
Outperform
Invitae price target raised to $30 from $21 at Oppenheimer
Oppenheimer analyst Kevin DeGeeter raised his price target for Invitae to $30 from $21 based on improved long-term competitive positioning for the company's patient-initiated testing given data presented at the ACMG meeting demonstrating poor performance for a leading DTC genetic test and potential consolidation in DTC market as industry matures and economies of scale, quality/clinical data and regulatory oversight drive market share. The analyst reiterates an Outperform rating on the shares.
04/23/19
BNCH
04/23/19
NO CHANGE
BNCH
UnitedHealth preferred lab launch a long-term plus for Invitae, says Benchmark
Benchmark analyst Bruce Jackson noted that UnitedHealthcare (UNH) plans to launch a Preferred Laboratory Network to include Invitae (NVTA), which he views as a long-term positive for the latter and "another building block for Invitae's strategy to make genetic testing more widely available and more easily reimbursed." Other labs named to the preferred network include LabCorp (LH), Quest Diagnostics (DGX), and BioReference and GeneDx, which are both part of Opko (OPK), the analyst noted. UnitedHealthcare's current network includes NeoGenomics (NEO) and he doesn't anticipate any impact to NeoGenomics from the preferred network launch, added Jackson.
11/27/19
OPCO
11/27/19
NO CHANGE
Target $34
OPCO
Outperform
Invitae 2020 guidance could be set conservatively, says Oppenheimer
Oppenheimer analyst Kevin DeGeeter, after speaking with management, continues to expect Invitae to provide Q4 revenue and 2020 guidance in mid-January. He believes 2020 offers Invitae "multiple avenues" for a growth rate "significantly above nearly all other publicly traded diagnostic companies." However, there is limited visibility on the pace of adoption curve or rate of market expansion, DeGeeter tells investors in a research note. As such, the analyst believes that if management provides 2020 guidance based on growth drivers with clearly established markets, which is their traditional approach, his $364.9M 2020 revenue estimate has downside risk. The analyst is above the consensus at $333.5M. DeGeeter keeps an Outperform rating on Invitae with a $34 price target. He believes such "conservative" guidance would have "paths to material upside."
LIVN LivaNova
$80.46

-2.93 (-3.51%)

09/29/19
PIPR
09/29/19
NO CHANGE
Target $90
PIPR
Overweight
LivaNova first patient enrollment in RECOVER 'an important step,' says Piper Jaffray
Piper Jaffray analyst Matt O'Brien notes that LivaNova announced it had enrolled the first patient in its CMS approved RECOVER clinical study. Although the timing is in-line with management's expectations, there had been some concern that it would slip, he notes, adding that the announcement is "certainly positive" and "an important step" for the company's topline outlook. On the whole, the analyst believes the announcement serves as a starting point for eventual coverage. O'Brien reiterates an Overweight rating and $90 price target on the shares.
09/06/19
PIPR
09/06/19
NO CHANGE
PIPR
Piper Jaffray says positive updates continue for LivaNova
Piper Jaffray analyst Matt O'Brien spoke to LivaNova's management following CMS approval the company's treatment-resistant depression, or TRD, protocol, and he views the updates positively and continues to see TRD as "one of the most exciting and large pipeline opportunities" for the company. O'Brien was also positive on the company's turnaround of its core Neuromod business due to its "solid" Q2 results, and maintained an Overweight rating and $90 price target on LivaNova shares.
11/20/19
PIPR
11/20/19
NO CHANGE
PIPR
Overweight
LivaNova restructuring decisions make sense, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien said he was not surprised by the news that LivaNova will be shutting down its Caisson Transcatheter Mitral Valve Replacement, or TMVR, program and begin restructuring its heart valve business given the structural and competitive pressures it faces. He believes these are decisions that make sense, as he does not believe there should be a material impact to the top-line but there will be a cost savings benefit, O'Brien tells investors. The analyst, who sees significant value creation coming from the company's evolving treatment-resistant depression, or TRD, franchise, keeps an Overweight rating on LivaNova shares.
11/25/19
STFL
11/25/19
NO CHANGE
Target $90
STFL
Buy
LivaNova price target raised to $90 after management meetings at Stifel
Stifel analyst Rick Wise noted that he hosted an investor dinner with LivaNova management in conjunction with the firm's healthcare conference last week, after which he has increased confidence in LivaNova's ongoing turnaround and transformation. CEO Damien McDonald emphasized the company will enter 2020 on a more solid foundation and management seemed confident the portfolio can drive sustained mid-single digits growth, Wise tells investors. Separately, the heart valve business restructuring and Caisson-TMVR program exit should aid focus and improve execution, said Wise, who raised his price target on LivaNova shares to $90 from $80 and keeps a Buy rating on the stock.
MNK Mallinckrodt
$3.28

-0.12 (-3.53%)

09/10/19
STFL
09/10/19
NO CHANGE
STFL
Mallinckrodt's sale of BioVectra helps alleviate cash pressure, says Stifel
Stifel analyst Annabel Samimy maintained a Hold rating and $8 price target on Mallinckrodt, but noted that Mallinckrodt announced the sale of its CDMO organization, BioVectra, to HIG Capital for a potential $250M, which the analyst believes is "a positive step to manage and bolster cash and maintain capital allocation priorities." Samimy added that, with the departure of Specialty Generics President Matthew Harbaugh, the company's suspension of the spin-off appears indefinite.
09/05/19
09/05/19
DOWNGRADE
Target $3

Market Perform
Mallinckrodt cut to Market Perform at BMO Capital on opioid restructuring report
As previously reported, BMO Capital analyst Gary Nachman downgraded Mallinckrodt to Market Perform and slashed his price target to $3 from $19 after yesterday's Bloomberg reports that the company hired restructuring firms to help manage through its opioid litigation. The analyst contends that an already challenging situation has "taken a turn for the worse", stating that he previously believed that the company would be able to navigate through these issues. Nachman adds that with the mounting pressures related to the litigation, the possibility of bankruptcy for Mallinckrodt can no longer be ruled out.
09/05/19
09/05/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. BHP Group (BHP) downgraded to Underperform from Neutral at Exane BNP Paribas. 2. Mallinckrodt (MNK) downgraded to Market Perform from Outperform at BMO Capital analyst Gary Nachman citing yesterday's Bloomberg reports that the company hired restructuring firms to help manage through its opioid litigation. 3. Yirendai (YRD) downgraded to Underperform from Neutral at Macquarie with analyst Dexter Hsu saying the company not only reported "disappointing" Q2 results, but also closed the merger with CreditEase on unfavorable terms. 4. Green Dot (GDOT) downgraded to Hold from Buy at Jefferies with analyst John Hecht saying the company's organic revenue growth has been slowing and it is trying to establish share in a new customer target market with well-resourced competitors. 5. Royal Dutch Shell (RDS.A, RDS.B) downgraded to Market Perform from Outperform at Cowen with analyst Jason Gabelman saying the downgrade reflects its peer leading exposure to international gas prices which are forecasted lower through 2020 and as a result could limit its free cash flow growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/09/19
STFL
09/09/19
NO CHANGE
Target $8
STFL
Hold
Mallinckrodt price target lowered to $8 from $20 at Stifel
Stifel analyst Annabel Samimy lowered her price target for Mallinckrodt shares to $8 from $20 after she reduced her expected growth of Acthar for 2019 and beyond and factored in more concrete potential litigation cash-calls. She models a $300M potential settlement with CMS related to the Acthar AMP-pricing reversion and has included a $900M potential liability for opioid-litigation payments, calling those her "best, reasonable estimates at this point" but acknowledging there still remains considerable uncertainty around both issues. Mallinckrodt's settlement of Track 1 of the Ohio multi-district litigations is "only a small step in the sprawling opioid litigation," but the settlement buys the company much-needed time to address New York state litigation or a global settlement, said Samimy, who keeps a Hold rating on Mallinckrodt shares.
MRNS Marinus Pharmaceuticals
$1.27

-0.05 (-3.79%)

09/26/19
HCWC
09/26/19
NO CHANGE
HCWC
Buy
Marinus' Phase 2 results an 'impressive win,' says H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao called ganaxolone's Phase 2 results in refractory status epilepticus an "impressive win" for Marinus Pharmaceuticals that he thinks should give "a much-needed boost" to investor sentiment on the drug's clinical utility. The analyst, who doesn't think investors assigned a high probability of success for RSE ahead of the data, keeps a Buy rating on Marinus shares.
10/18/19
CANT
10/18/19
INITIATION
Target $7
CANT
Overweight
Marinus Pharmaceuticals assumed with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young assumed coverage of Marinus Pharmaceuticals with an Overweight rating and $7 price target. The company's lead asset, ganaxalone, is currently in two Phase 3 studies and another is planned to start in 2020 and she thinks expectations are low for all three programs. She is most focused on refractory status epilepticus, or RSE, as an underappreciated opportunity, but also notes that Marinus could launch ganaxolone in CDKL5 deficiency disorder as early as 2021.
07/24/19
PIPR
07/24/19
NO CHANGE
Target $206
PIPR
Overweight
Sage competitive risks diminished with Marinus setback, says Piper Jaffray
Piper Jaffray analyst Danielle Brill says Marinus Pharmaceuticals' (MRNS) failure of two Phase 2 studies in post-partum depression diminishes the competitive risk for Sage Therapeutics (SAGE). Marinus' setback is a net positive for Sage, as it is unlikely that ganaxolone will be a competitive threat "anytime soon," Brill tells investors in a research note. While ganaxolone is likely effective when administered as an IV, it appears that efficacy was compromised in an attempt to optimize convenience, adds the analyst. Following yesterday's data, Brill sees Sage's SAGE-217 as the only viable oral agent in its class. She maintains an Overweight rating on Sage Therapeutics with a $206 price target.
09/03/19
HCWC
09/03/19
INITIATION
Target $5
HCWC
Buy
Marinus Pharmaceuticals initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao started Marinus Pharmaceuticals with a Buy rating and $5 price target. Disappointments in focal onset seizures and Fragile X syndrome in 2016 have overshadowed the "robust" Phase 2 data produced in rare orphan epilespies, Tsao tells investors in a research note. Considering peak sales potential in excess of $125M for CDLK5 and $250M for PCDH19, the analyst expects Marinus shares to "appreciate meaningfully" if each of those studies succeeds. He believes CDD and PCDH could each alone be worth up to $2.50 and $8.00 per share, respectively.
MDT Medtronic
$111.12

-2.02 (-1.79%)

11/25/19
ARGS
11/25/19
NO CHANGE
Target $135
ARGS
Buy
Medtronic price target raised to $135 from $120 at Argus
Argus analyst David Toung raised his price target on Medtronic to $135 and kept his Buy rating after its Q2 earnings beat that was driven by growth upside in Restorative Therapies Group and the Minimally Invasive Therapies Group businesses. The analyst also cites the company's "solid performance in emerging markets" and the strong sales of its diabetes products overseas, raising his FY20 and FY21 EPS views by 3c and 2c to $5.63 and $6.12 respectively.
12/03/19
GUGG
12/03/19
NO CHANGE
Target $8
GUGG
Buy
Strategic element of ViewRay news 'more profound' than capital, says Guggenheim
Guggenheim analyst Chris Pasquale said he believes ViewRay's (VRAY) plans to issue $75M in new equity "should go a long way toward mitigating" investor concerns about the company's cash burn and balance sheet. However, as important as this improved liquidity is, he sees the strategic implications of collaborations with both Elekta (EKTAY) and Medtronic (MDT) as "even more profound," telling investors that the participation of two large, strategic partners in the equity raise is a significant endorsement of ViewRay's technology. Pasquale reiterates his Buy rating on ViewRay shares, which are up $1.10, or 32% to $4.50 in pre-market trading.
11/20/19
DBAB
11/20/19
NO CHANGE
Target $123
DBAB
Buy
Medtronic price target raised to $123 from $118 at Deutsche Bank
Deutsche Bank analyst Pito Chickering raised Medtronic's price target to $123 from $118 saying the company's Q2 "brought no major surprises." The analyst expects sales growth acceleration in the second half of the fiscal year and 2021 and keeps a Buy rating on the shares.
12/03/19
MZHO
12/03/19
NO CHANGE
Target $9
MZHO
Buy
Mizuho views ViewRay deals, capital raise favorably
ViewRay (VRAY) last night announced the signature of non-binding memoranda of understanding with Elekta AB (EKTAY) and Medtronic (MDT) as well as a common stock offering for $75M, Mizuho analyst Difei Yang tells investors in a research note. Elekta and Medtronic are taking stakes in ViewRay as part of the stock offering, the analyst points out. Yang views these announcements favorably and believes they are further validation of ViewRay's MRIdian technology in addition to removing its financing overhang. The analyst reiterates a Buy rating on the shares with a $9 price target.
NTUS Natus Medical
$31.37

-0.19 (-0.60%)

NVS Novartis
$92.55

0.47 (0.51%)

11/25/19
OPCO
11/25/19
DOWNGRADE
Target $85
OPCO
Perform
The Medicines Co. downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Jay Olson downgraded The Medicines Co. (MDCO) to Outperform from Perform with a price target of $85, up from $68, after it agreed to be acquired by Novartis (NVS) for $9.7B. After months of impressive data presentations for inclisiran and media reports of alleged negotiations with potential acquirers, Olson says that this this deal announcement brings welcomed news to The Medicines Co. investors who were patient enough to "weather an exciting ride."
11/25/19
BARD
11/25/19
UPGRADE
Target $70
BARD
Outperform
Arrowhead upgraded to Outperform after Medicines Company takeover at Baird
As previously reported, Baird analyst Madhu Kumar upgraded Arrowhead Pharmaceuticals (ARWR) to Outperform from Neutral with a price target of $70, up from $39, after Medicines Company (MDCO) announced a definitive agreement to be acquired by Novartis (NVS). That deal forces Kumar to re-evaluate Arrowhead' RNAi platform, which is heavily levered to lipid-modifying RNAi drugs for cardiovascular disease, the analyst tells investors. Given the early positive efficacy for Arrowhead's ANGPTL3 and APOC3 RNAi drugs presented at the American Heart Association meeting, Kumar believes these programs have "the chance to dominate the ANGPTL3 and APOC3 landscapes," though cautions both are "quite early."
12/04/19
BOFA
12/04/19
NO CHANGE
Target $104
BOFA
Buy
BofA/Merrill recommends investors buy Novartis on new product growth
BofA/Merrill analyst Graham Parry keeps his Buy rating and CHF104 price target on Novartis in spite of lowering his FY20 EPS view to $5.64 from $5.92 to reflect the dilution from its Medicines Co acquisition and expected completion of the US generics divestment to Aurobindo. The analyst cites the company's expected new launches and forecasts "premium growth" from its new products, saying its sales are set to rise about 7% in 2019-2022 thanks to its "16 key growth products and Pharma margin expansion" to 37.1% from 33.3% this year.
12/06/19
CANT
12/06/19
INITIATION
Target $34
CANT
Overweight
Gossamer Bio initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Eliana Merle initiated coverage of Gossamer Bio (GOSS) with an Overweight rating and $34 price target. The analyst sees a "compelling" setup into 2020. While the Luster data from Novartis (NVS) has significant stock moving potential for Gossamer, with upside potential of 75%-100% versus downside of 25%-50%, GB002 for pulmonary arterial hypertension could be a $2B peak sales opportunity with potential de-risking in the first half of 2020 "that deserves more focus," Merle tells investors in a research note.
PTCT PTC Therapeutics
$48.22

-0.95 (-1.93%)

12/09/19
RHCO
12/09/19
NO CHANGE
RHCO
The 21 smaller cap stocks SunTrust sees rallying over 20% in 2020
SunTrust polled its 34 research analysts to get their highest conviction small- and mid-cap ideas with at least 20% upside potential for 2020. The list is as follows: eHealth (EHTH), Workiva (WK), Wix.com (WIX), SailPoint (SAIL), Euronet (EEFT), Stitch Fix (SFIX), Winnebago (WGO), Newell Brands (NWL), Eldorado Resorts (ERI), Marriott Vacations (VAC), PTC Therapeutics (PTCT), Momenta (MNTA), BioDelivery Sciences (BDSI), Axsome Therapeutics (AXSM), HD Supply (HDS), Huntsman (HUN), Targa Resources (TRGP), PDC Energy (PDCE), Parsley Energy (PE), Encore Capital (ECPG) and First Horizon (FHN).
10/30/19
SBSH
10/30/19
NO CHANGE
Target $55
SBSH
Buy
PTC Therapeutics Q3 report an incremental negative for shares, says Citi
Citi analyst Joel Beatty lowered his price target for PTC Therapeutics to $55 from $62 saying the company's Q3 earnings report is an incremental negative for the stock. The familial dysautonomia splicing program was discontinued, Friedreich's ataxia gene therapy investigational new drug application was delayed from the end of 2019 to mid-2020, 2019 opex guidance was increased by $20M, and Tegsedi market size estimate appears to have dropped to 5,000 from 6,000, Beatty tells investors in a research note. The analyst, however, keeps a Buy rating on the shares.
12/05/19
RBCM
12/05/19
NO CHANGE
Target $58
RBCM
Outperform
PTC Therapeutics price target raised to $58 from $47 at RBC Capital
RBC Capital analyst Brian Abrahams raised his price target on PTC Therapeutics to $58 and kept his Outperform rating after meeting with its management. The analyst says the company "sounded confident" about the profile and market opportunity of risdiplam, the continued progress in its lead gene therapy program GT- AADC, and the early development stage signs within its Huntington's program. Abrahams believes that there is still opportunity for share appreciation for PTC Therapeutics.
11/12/19
RHCO
11/12/19
INITIATION
Target $78
RHCO
Buy
PTC Therapeutics initiated with a Buy at SunTrust
SunTrust analyst Robyn Karnauskas initiated coverage of PTC Therapeutics with a Buy rating and $78 price target. The analyst believes that the stock can "move a lot" if the company's launches go better than expected, noting that with two marketed products, 4 new launches in the next 12 months, and the possibility to break even in the next 2-3 years, investors are only missing "leverage" to get behind the name.
SUPN Supernus
$22.69

-0.145 (-0.63%)

11/08/19
BREN
11/08/19
DOWNGRADE
Target $24
BREN
Hold
Supernus downgraded to Hold from Buy at Berenberg
Berenberg analyst Patrick Trucchio downgraded Supernus to Hold from Buy with a $24 price target.
11/06/19
JEFF
11/06/19
DOWNGRADE
Target $23
JEFF
Hold
Supernus downgraded to Hold from Buy at Jefferies
Jefferies analyst David Steinberg downgraded Supernus Pharmaceuticals to Hold from Buy with a $23 price target.
11/06/19
JEFF
11/06/19
DOWNGRADE
Target $23
JEFF
Hold
Jefferies downgrades Supernus to Hold, cuts target to $23 from $46
Jefferies analyst David Steinberg downgraded Supernus Pharmaceuticals to Hold from Buy with a price target of $23, down from $46. The company's revenue and earnings in Q3 were below estimates and the SPN-810 Phase 3 date in attention deficit hyperactivity disorder impulse aggression missed, Steinberg tells investors in a research note. Further, the SPN-812 new drug application has yet to be filed, adds the analyst.
11/07/19
STFL
11/07/19
DOWNGRADE
Target $23
STFL
Hold
Supernus downgraded to Hold from Buy at Stifel
Stifel analyst Annabel Samimy downgraded Supernus Pharmaceuticals to Hold from Buy with a price target of $23, down from $55. The analyst cites the Phase 3 miss for SPN-810/IA for the downgrade, an asset he views a "critical replacement" for Trokendi. While Supernus is holding out for the second Phase 3 result before determining the program's viability, the analyst says he can no longer count on SPN-810's contribution given a likely extended development pathway, even if the second trial is successful. Further, more disappointing is the third revenue miss this year, Samimy tells investors in a post-earnings research note. Reduced growth prospects for Trokendi, "insufficient offset" from Oxtellar, and removal of SPN-810 "has meaningfully impacted future cash flows," says the analyst.
WTKWY Wolters Kluwer
$0.00

(0.00%)

05/17/19
JPMS
05/17/19
DOWNGRADE
JPMS
Underweight
Wolters Kluwer downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Daniel Kerven downgraded Wolters Kluwer to Underweight from Neutral with a price target of 57 euros.
XENE Xenon Pharmaceuticals
$13.86

-0.06 (-0.43%)

09/20/19
GUGG
09/20/19
INITIATION
Target $25
GUGG
Buy
Guggenheim starts Xenon Pharmaceuticals at Buy, sees good odds for lead asset
As previously reported, Guggenheim analyst Yatin Suneja initiated Xenon Pharmaceuticals with a Buy rating and $25 price target. The analyst likes the company's focus on developing precision therapies for rare genetic epileptic conditions and sees its lead asset, XEN496, having "a relatively high probability of success." Meanwhile, pipeline product XEN1101 offers an attractive profile in adult focal epilepsy and XEN901 has the potential to offer better efficacy than current sodium channel blockers, said Suneja.
09/20/19
GUGG
09/20/19
INITIATION
Target $25
GUGG
Buy
Xenon Pharmaceuticals initiated with a Buy at Guggenheim
Guggenheim analyst Yatin Suneja initiated Xenon Pharmaceuticals with a Buy and $25 price target.
03/29/19
STFL
03/29/19
INITIATION
Target $21
STFL
Buy
Xenon Pharmaceuticals price target raised, coverage transferred at Stifel
Stifel analyst Paul Matteis took over coverage of Xenon Pharmaceuticals from Stephen Willey with a maintained Buy rating and raised price target of $21, up from the prior target of $18. Matteis believes just one of Xenon's three lead epilepsy assets needs to succeed to drive the stock meaningfully higher from current levels, he tells investors.
ZBH Zimmer Biomet
$146.71

-1.84 (-1.24%)

12/04/19
RAJA
12/04/19
UPGRADE
Target $170
RAJA
Strong Buy
Zimmer Biomet upgraded to Strong Buy at Raymond James, PT raised to $170
Raymond James analyst Lawrence Keusch upgraded Zimmer Biomet to Strong Buy from Outperform with a price target of $170, up from $160. In a research note to investors, Keusch says that while accelerating growth has underpinned his prior positive rating, opportunities to reduce obsolete inventory charges and inventory over the next several years increase his conviction in further shareholder value creation. The analyst calls out Zimmer's annual inventory charges, which are well above large-cap comparables at over $200M. He further states that the potential for an inflection in free cash flow and potential EPS upside may not yet be fully appreciated by investors as it is early and the shares under-owned by large long-only investors, improving fundamentals and cash flow dynamics could drive incremental ownership.
12/04/19
RAJA
12/04/19
UPGRADE
Target $170
RAJA
Strong Buy
Zimmer Biomet upgraded to Strong Buy from Outperform at Raymond James
Raymond James analyst Lawrence Keusch upgraded Zimmer Biomet to Strong Buy from Outperform with a $170 price target.
11/06/19
LEER
11/06/19
NO CHANGE
Target $160
LEER
Outperform
Zimmer Biomet price target raised to $160 from $155 at SVB Leerink
SVB Leerink analyst Richard Newitter raised his price target for Zimmer Biomet to $160 from $155, saying Zimmer represents an attractive turnaround story at a compelling valuation and is one of his favorite large-cap picks, especially as revenue growth acceleration looks set to start taking form in a more meaningful way into 2020-2021. Newitter says the company's quarterly performance, plus management's commentary that it sees a pathway for acceleration beyond 2%-3% for 2020 without the need for M&A increases his confidence in an upward estimate revision bias towards his above-consensus out-year estimates. The analyst keeps an Outperform rating on the shares.
11/06/19
RAJA
11/06/19
NO CHANGE
Target $160
RAJA
Outperform
Zimmer Biomet price target raised to $160 from $150 at Raymond James
Raymond James analyst Lawrence Keusch raised his price target for Zimmer Biomet to $160 from $150 and maintained an Outperform rating following the company's "solid' Q3 results, which he says supports a story of incremental improvement for a company with leading global market share and a management team focused on execution.
ZGNX Zogenix
$46.82

-0.02 (-0.04%)

08/26/19
PIPR
08/26/19
NO CHANGE
PIPR
Overweight
Zogenix should be bought on weakness from Modis deal, says Piper Jaffray
Piper Jaffray analyst Danielle Brill recommends buying shares of Zogenix on weakness following the company's acquisition of Modis Therapeutics. While pipeline diversification makes sense, investors are likely thrown off by the timing of the deal, given the proximity to Fintepla approval, Brill tells investors in a research note. Also, a potential near-term takeover of Zogenix now seems unlikely, adds the analyst. However, she still thinks Fintepla will be a commercial success. Brill expects Zogenix shares to recover after the new drug application filing is accepted and she keeps an Overweight rating on the name with a $64 price target. The stock in afternoon trading is down 13%, or $6.68, to $43.33.
06/28/19
MZHO
06/28/19
NO CHANGE
Target $65
MZHO
Buy
Zogenix price target raised to $65 from $58 at Mizuho
Mizuho analyst Difei Yang raised her price target for Zogenix to $65 from $58 following the FDA's decision to allow a re-submission of the new drug application for Fintepla. The analyst believes a priority review is highly likely and views the FDA's decision as a positive. She reiterates a Buy rating on Zogenix shares.
10/21/19
NEED
10/21/19
INITIATION
Target $58
NEED
Buy
Zogenix initiated with a Buy at Needham
Needham analyst Serge Belanger initiated coverage of Zogenix with a Buy rating and $58 price target, citing its Fintepla drug returning to the path of a potential regulatory approval by the FDA. The analyst contends that the drug will play a "niche but consequential role" in treating rare pediatric epilepsy disorders given the high levels of efficacy and seizure freedom in treating Dravet Syndrome, or DS, patients. Belanger believes that Fintepla will be approved by the FDA in the first half of next year thanks to its efficacy and manageable safety profile, as well as a "significant unmet need in DS."
12/06/19
PIPR
12/06/19
NO CHANGE
Target $64
PIPR
Overweight
2020 looking to be 'transformational year' for Zogenix, says Piper Jaffray
Piper Jaffray analyst Danielle Brill reiterated an Overweight rating and $64 price target on Zogenix after hosting an epilepsy panel and fireside chat with Zogenix CEO Stephen Farr this week. Brill said that 2020 is looking to be a "transformational year" for the company with Fintepla Pivotal Phase 3 Lennox-Gastaut Syndrome data reading in the first quarter and potential approval/commercial launch for Dravet Syndrome. The analyst said she discussed the prospects for the drug during the firm's expert panel and feedback continues to be "positive," adding that she believes Fintepla will be approved for DS and sees the launch being "successful." Brill added that she is optimistic that the Phase 3 LGS trial will be "positive" and the drug will be "impactful" for that indication as well.

TODAY'S FREE FLY STORIES

FCAU

Fiat Chrysler

$13.51

-0.135 (-0.99%)

, PUGOY

Peugeot

$0.00

(0.00%)

12:25
01/22/20
01/22
12:25
01/22/20
12:25
Periodicals
Fiat Chrysler CEO says PSA deal talks 'progressing really well,' Reuters says »

Fiat Chrysler (FCAU) CEO…

FCAU

Fiat Chrysler

$13.51

-0.135 (-0.99%)

PUGOY

Peugeot

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APHA

Aphria

$5.66

0.345 (6.49%)

12:25
01/22/20
01/22
12:25
01/22/20
12:25
Options
Aphria call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:25
01/22/20
01/22
12:25
01/22/20
12:25
Conference/Events
The Executives' Club of Chicago to hold a luncheon meeting »

The Executives' Club…

SRPT

Sarepta

$121.03

-1.65 (-1.34%)

12:24
01/22/20
01/22
12:24
01/22/20
12:24
Periodicals
New documents point to 'deeper' FDA concerns about Sarepta's Vyondys, STAT says »

New documents released…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTI

Proteostasis

$1.96

0.04 (2.08%)

12:17
01/22/20
01/22
12:17
01/22/20
12:17
Hot Stocks
Proteostasis to present data from organoid study in CF treatment »

Proteostasis Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
01/22/20
01/22
12:17
01/22/20
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRNA

Moderna

$21.97

1 (4.77%)

12:16
01/22/20
01/22
12:16
01/22/20
12:16
Recommendations
Moderna analyst commentary  »

Moderna mRNA technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
01/22/20
01/22
12:16
01/22/20
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:15
01/22/20
01/22
12:15
01/22/20
12:15
General news
Oil Action: WTI crude »

Oil Action: WTI crude hit…

TWLO

Twilio

$119.62

0.47 (0.39%)

12:12
01/22/20
01/22
12:12
01/22/20
12:12
Periodicals
Breaking Periodicals news story on Twilio »

Hedgeye adds Twilio to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 24

    Feb

NFLX

Netflix

$332.00

-6.24 (-1.84%)

, IBM

IBM

$143.22

4.07 (2.92%)

12:12
01/22/20
01/22
12:12
01/22/20
12:12
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks are rebounding…

NFLX

Netflix

$332.00

-6.24 (-1.84%)

IBM

IBM

$143.22

4.07 (2.92%)

AAPL

Apple

$318.43

2.04 (0.64%)

ETN

Eaton

$97.23

2.72 (2.88%)

ABT

Abbott

$92.33

2.57 (2.86%)

NAVI

Navient

$15.02

1.16 (8.37%)

ARNC

Arconic

$28.60

-0.795 (-2.71%)

FCEL

FuelCell

$2.14

-0.735 (-25.61%)

NTRS

Northern Trust

$102.32

-6.35 (-5.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 27

    Jan

  • 28

    Jan

  • 04

    Feb

NTDOY

Nintendo

$0.00

(0.00%)

12:09
01/22/20
01/22
12:09
01/22/20
12:09
Periodicals
Judge says iLife's patent suit against Nintendo not valid, Verge says »

Federal Judge Barbara…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WILC

G. Willi-Food

$12.22

-0.21 (-1.69%)

12:06
01/22/20
01/22
12:06
01/22/20
12:06
Hot Stocks
G. Willi-Food CEO Michael Luboschitz to resign for personal reasons »

G. Willi-Food…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ELAN

Elanco

$31.41

0.77 (2.51%)

12:05
01/22/20
01/22
12:05
01/22/20
12:05
Options
Elanco Animal Health call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 23

    Jan

HUYA

Huya

$18.73

-1.75 (-8.54%)

12:00
01/22/20
01/22
12:00
01/22/20
12:00
Hot Stocks
Huya falls -8.5% »

Huya is down -8.5%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMRE

Costamare

$9.01

-1.34 (-12.95%)

12:00
01/22/20
01/22
12:00
01/22/20
12:00
Hot Stocks
Costamare falls -12.9% »

Costamare is down -12.9%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CANG

Cango

$7.28

-0.71 (-8.89%)

12:00
01/22/20
01/22
12:00
01/22/20
12:00
Hot Stocks
Cango falls -9.3% »

Cango is down -9.3%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OCFT

OneConnect

$15.17

1.2 (8.59%)

12:00
01/22/20
01/22
12:00
01/22/20
12:00
Hot Stocks
OneConnect rises 8.5% »

OneConnect is up 8.5%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDRBF

Bombardier

$0.00

(0.00%)

12:00
01/22/20
01/22
12:00
01/22/20
12:00
Periodicals
Bombardier subway cars returning to service this week in NYC, Reuters says »

Bombardier subway cars…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

FSB

Franklin Financial Network

$38.25

4.13 (12.10%)

12:00
01/22/20
01/22
12:00
01/22/20
12:00
Hot Stocks
Franklin Financial Network rises 12.6% »

Franklin Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXPR

Express

$4.88

0.73 (17.59%)

12:00
01/22/20
01/22
12:00
01/22/20
12:00
Hot Stocks
Express rises 17.5% »

Express is up 17.5%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

BTI

British American Tobacco

$44.63

0.06 (0.13%)

11:56
01/22/20
01/22
11:56
01/22/20
11:56
Upgrade
British American Tobacco rating change  »

British American Tobacco…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPR

Spirit AeroSystems

$64.32

-0.24 (-0.37%)

11:55
01/22/20
01/22
11:55
01/22/20
11:55
Options
Spirit AeroSystems put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HARL

Harleysville Savings Financial Corp

$0.00

(0.00%)

11:53
01/22/20
01/22
11:53
01/22/20
11:53
Earnings
Harleysville reports Q1 EPS 50c vs. 57c last year »

Q1 net income included a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

HARL

Harleysville Savings Financial Corp

$0.00

(0.00%)

11:51
01/22/20
01/22
11:51
01/22/20
11:51
Hot Stocks
Harleysville increases quarterly cash dividend 8% »

Harleysville Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.